Lung transplantation is the ultimate treatment of patients with severe lung disease. However, the short- and long-term prognosis is still problematic due to immunological reactions towards the transplanted lung.

The first patient was successfully included January 2021 in the Chronic Lung Allograft dysfunction (Lung transplant rejection) phase I-II trial. The patients are randomized to a blinded treatment with intravenous infusion of either 100 million ASCs, 200 million ASCs or saline. A total of seven of the planned 30 patients have been included without any problems.